Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health

Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health
Humacyte gains Israel Symvess review

The Israel Ministry of Health has accepted Humacyte Marketing Authorization Application for its Symvess acellular, tissue engineered vessel intended for urgent arterial injury repair.

A review period of 180 working days has been established by the ministry to evaluate the application. This marks a significant step in the regulatory process for Symvess as Humacyte seeks to expand access to this technology in new markets.

Humacyte has reaffirmed its commitment to medical innovation and patient outcomes, marking World Health Day with new initiatives focused on healthier futures for patients, according to a recent update from the company. Earlier this year, the firm participated in vascular meetings to present its Symvess and ATEV vessel technologies to industry experts. These efforts come as the company seeks to advance regulatory approvals and broaden market access for its engineered vessel products.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.